Key Takeaways for UnitedHealth Group Stock as of August 2026
- YTD Reversal: UnitedHealth Group (UNH) stock has returned 19.6% year to date, a 34.2% annualized pace, after bottoming near a $271 close on March 31 and rallying on a July 16 earnings beat.
- Model Gap: TIKR’s mid case values UNH stock at $723, about 80% above today’s price.
- Cost Turn: Medical costs ran at 86.70% of premiums in the second quarter, beating the 88.47% Street estimate and last year’s 89.4%.
- Target Split: The Street carries 16 buys, 6 outperforms, 5 holds, and 1 sell on UNH stock, with a mean target of $475 sitting 18% above the current price, even as that mean target climbed 15% over the past six weeks while the stock slipped 3%.
The gap between UNH stock’s price and where the Street and TIKR’s model see it heading is worth tracking. Analyze UNH stock on TIKR for free →
UnitedHealth Stock’s 20% YTD Run Traces Back to One Earnings Report
UnitedHealth Group (UNH) stock has returned 19.6% year to date, a 34.2% annualized pace, but almost none of that gain arrived gradually. Shares fell to a $271 close on March 31, deep in a slide that started with 2025’s cost overruns, then jumped nearly 8% in a single session on July 16 after the company beat second quarter estimates and raised its 2026 outlook.
The numbers behind that move are specific. UnitedHealth earned an adjusted $6.38 per share against a Street estimate of $4.90. Its medical cost ratio, the share of premium revenue spent on patient care, fell to 86.70% from 89.4% a year earlier and came in well under the 88.47% analysts had modeled. Management used the beat to raise 2026 adjusted earnings guidance to a range of $19.50 to $20.00 per share, up from a prior floor of at least $17.75 and above the $18.47 the Street had penciled in.
UnitedHealthcare CEO Tim Noel was careful about how he framed that improvement on the Q2 earnings call: “It’s really important to note this does not represent an inflection point in trend. We’re continuing at those high levels, but it’s coming in lower than our benefit planning assumptions.” That distinction matters. The stock’s entire 2025 collapse was a story about cost control slipping out of management’s hands, so a quarter where the company can point to specific pricing and plan-design changes as the cause, rather than a favorable claims environment, is a different kind of evidence.
Shares have since cooled from the mid-$400s reached right after the report to $402.19 by August 11, still up sharply from the April trough but no longer running. UnitedHealthcare CEO Tim Noel told investors that margin recovery in the commercial insurance business, which includes Obamacare plans, will take longer than the company first expected. The YTD run is a bet that a three-year cost problem is actually getting fixed, not a bet that the market is about to pay a richer multiple for the same earnings.
See how the Street’s price targets on UNH stock have moved since the July earnings beat. Analyze UNH stock on TIKR for free →
Street Analysts Have Kept Raising UNH Stock’s Target Even as Shares Cooled
Twenty-six analysts currently publish price targets on UnitedHealth Group stock, split 16 buys, 6 outperforms, 5 holds, and 1 sell. Their mean target sits at $475, which is 18% above the $402 close, and that gap has been widening from an unusual direction: not because the stock fell, but because analysts keep raising the target.
At the June 30 mark, the mean target stood at $412 against a $416 close, meaning the Street was barely above the stock price at all. By August 11, the mean had climbed 15% to $475 while the stock itself slipped 3% to $402. That is analysts turning more bullish precisely as the post-earnings pop lost steam, not chasing a rally higher. Go back further and the pattern holds: at the March 31 trough, the mean target was $359 against a $271 close, a 33% gap.
The stock has since risen 49% off that low, and the mean target has risen right along with it, up 32% over the same stretch. The Street has not been caught flat-footed by this move. It has been recalibrating in real time.
TIKR Values UNH Stock at $723, Pricing In a Multiyear Cost Recovery
TIKR’s mid case model values UnitedHealth Group at $723 by December 2030, implying a total return of 80% from the current $402 price, or 14% annualized over 4.4 years.
That annualized return sits well above what a mature, low-growth managed care business typically commands, and the multiple confirms there’s room left to capture it.
UNH stock trades at 19x forward normalized earnings, below its four-and-a-half-year mean of 19.56x and well under the 25.23x high it hit in 2022, even after the stock’s 49% run off the April low.
The model’s longer horizon is also why its implied upside runs so far ahead of the Street’s 18%: TIKR is pricing a full multiyear normalization of the medical cost ratio and the return of commercial margin growth that Noel said would take time, while sell-side targets are still anchored to the next twelve months. If the second quarter’s cost discipline persists rather than proving to be a one-off, the model’s case gets easier to make each quarter.
TIKR’s model puts UNH stock’s target at $723. Check the assumptions behind that number yourself. Analyze UNH stock on TIKR for free →
Should You Invest in UnitedHealth Group Incorporated?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UnitedHealth Group Incorporated stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth Group Incorporated alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze UNH stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
